The Richardson Centre for Functional Foods and Nutraceuticals is five years old and to mark the occasion it was joined by the Honourable Erin Selby, Minister of Advanced Education and Literacy, as it signed two international research agreements
News & Media
The Sanford Project & DiaMedica announced the successful completion of a study involving DM-199 in preventing the onset of Type 1 diabetes in the non-obese diabetic mouse model
GVI Clinical Development Solutions Inc. and Guangzhou, China based Guangzhou IRD Medicine Company, announce the signing of a Memorandum of Understanding to create a joint venture company called IRD-CDS, based in China
Premier Greg Selinger announced a new Science Education Action Plan that includes $25 million over five years for science classroom renewal, teacher training and new strategic partnerships to promote Manitoba's science programming
Regulations for foods and natural health products, and what you can say about them, vary from country to country.
DiaMedica announced the company's entry into an evaluation agreement with the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health
Valeant filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc. for removal of Cephalon's current Board of Directors and election of its seven nominees in their
Premier Greg Selinger today announced the province is committing to invest $70 million in a new-state-of-the-art facility for CancerCare Manitoba to improve diagnostics, treatment and research that will help Manitoba families affected by this disease.
Valeant Pharmaceuticals International, Inc. announced that it had made a proposal to the Board of Directors of Cephalon, Inc. to acquire Cephalon for $73.00 per share in cash
Kane Biotech announced a non-brokered private placement offering for gross proceeds of up to $1,500,000 from the sale of up to 12,500,000 units at a price of $0.12 per unit
IMRISNV will provide important new capabilities for clinicians at University of Utah Hospital's leading edge stroke center
Valeant Pharmaceuticals International is Among the Companies in the Healthcare Sector With the Best Relative Performance
Valeant Pharmaceuticals International ranks first among companies in the Healthcare sector as measured by relative performance
A two-year-long clinical study on the health benefits of flax seeds is complete and, depending on the results, it could yield a rich supply of potential products for commercialization
The Governments of Canada and Manitoba are investing $400,000 to help survey Manitobans about their opinions, preferences and experiences with food and health which will lead to food development and creating a healthier future for Manitobans
Cangene returned to profitability in the second quarter with revenue up compared to the year before
Provincial and Federal Governments Commit More Than $406,000 to Agri-Health Research Network in Manitoba
The Governments of Canada and Manitoba are committing $406,000 in funding in 2010/11 to the Manitoba Agri-Health Research Network Inc. (MAHRN) to support the further research, development and commercialization of projects that identify links between food
The Governments of Canada and Manitoba announced they are contributing to a $10 million strategic initiative to enhance the capacity of the province’s medical device industry to develop and commercialize specialized joint replacement technology
DiaMedica announced antihypertensive results with its lead monoclonal antibody DM-204. Consistent and significant blood pressure lowering results are observed with DM-204 in all animals and the lower blood pressure occurred for the duration of the study
IMRIS Inc. announced the sale of IMRISneuro to the University Hospital Tübingen, located in Tübingen, Germany.
AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment
Valeant Pharmaceuticals International, Inc. announces fourth quarter financial results for 2010.